Optical coherence tomography (OCT) system maker Michelson Diagnostics, which focuses on multi-beam OCT technology, has data that shows significant improvement in basal cell carcinoma (BCC) diagnosis using its VivoSight multi-beam OCT scanner. In addition to being an efficient, noninvasive way to diagnose BCC and other non-melanoma skin cancers, the scanner has the potential to reduce biopsies, surgery, and scarring for patients.
Joint lead investigator Dr. Martina Ulrich of CMB Collegium (Berlin, Germany) outlined the results of the independent multi-center, prospective clinical study into the use of VivoSight, and discussed their implications for BCC diagnosis and management at the World Congress of Dermatology, which took place June 8-13, 2015, in Vancouver, BC, Canada. The study was first published online in the British Journal of Dermatology in April 2015.
Andy Hill, Michelson Diagnostics' CEO, notes that the company is expanding the scanner's availability in Germany and select territories in Europe. The system has CE/TGA and FDA regulatory clearances in the U.S., and is available for sale in Europe, the U.S., and Australia.
Follow us on Twitter, 'like' us on Facebook, connect with us on Google+, and join our group on LinkedIn